NIFTY 50

Bharat Biotech’s partner Ocugen to pursue final approval for Covaxin use in US

Updated : June 11, 2021 15:51:54 IST

The US Food and Drug Administration (FDA) has recommended Ocugen, the US partner of Indian vaccine maker Bharat Biotech, to pursue a final approval for COVID-19 vaccine Covaxin instead of getting Emergency Use Authorisation (EUA).

Ocugen will now pursue submission of a biologics licence application (BLA) for Covaxin. The BLA is a full approval mechanism by the FDA for drugs and vaccines.

The pharma firm is in talks with the FDA regarding the additional documents and information required for the BLA submission to bring Covaxin to the US.

The US drug regulator had last month revised the guidelines for COVID-19 vaccine approvals and said that they will no longer grant EUAs to new vaccine applications.

Watch the video for more.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV

recommended for you